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Hyperactivation of ATM upon DNA-PKcs 
inhibition modulates p53 dynamics and cell 
fate in response to DNA damage
ABSTRACT A functional DNA damage response is essential for maintaining genome integrity 
in the presence of DNA double-strand breaks. It is mainly coordinated by the kinases ATM, 
ATR, and DNA-PKcs, which control the repair of broken DNA strands and relay the damage 
signal to the tumor suppressor p53 to induce cell cycle arrest, apoptosis, or senescence. Al-
though many functions of the individual kinases have been identified, it remains unclear how 
they act in concert to ensure faithful processing of the damage signal. Using specific inhibi-
tors and quantitative analysis at the single-cell level, we systematically characterize the con-
tribution of each kinase for regulating p53 activity. Our results reveal a new regulatory inter-
play in which loss of DNA-PKcs function leads to hyperactivation of ATM and amplification of 
the p53 response, sensitizing cells for damage-induced senescence. This interplay determines 
the outcome of treatment regimens combining irradiation with DNA-PKcs inhibitors in a p53-
dependent manner.
INTRODUCTION
The DNA damage response (DDR) is an essential process that pro-
tects the integrity of the genome and prevents cancerogenic trans-
formations. In mammalian cells, sophisticated mechanisms evolved 
to sense various kinds of DNA damage and adjust cellular physiol-
ogy by arresting the cell cycle, activating repair mechanisms, or in-
ducing senescence and apoptosis (Ciccia and Elledge, 2010). 
Among the most dangerous DNA lesions are double-strand breaks 
(DSBs), as they can lead to chromosomal aberrations and cellular 
transformation when left unrepaired. Three kinases belonging to the 
phosphatidylinositol 3-kinase (PI3K)–like kinase family coordinate 
the response to DSBs: ataxia telangiectasia-mutated (ATM; Harper 
and Elledge, 2007), ataxia telangiectasia and Rad3-related (ATR; 
Cimprich and Cortez, 2008), and DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs; Chiruvella et al., 2013). The activation 
of these nuclear serine/threonine kinases follows a complex pattern 
that changes over time and depends on the cell cycle state, the 
nature of the induced breaks, and the repair pathways used (Ciccia 
and Elledge, 2010). ATM is activated immediately upon damage 
and mediates repair of DSBs by both nonhomologous end joining 
(NHEJ) and homologous recombination (HR). DNA-PKcs activation, 
in contrast, is restricted to breaks repaired by canonical NHEJ 
(cNHEJ). ATR is activated at later stages of the response by the pres-
ence of single-stranded DNA, which is mainly exposed during HR.
The activity of the kinases leads to the modification of chromatin 
and the assembly of large multiprotein complexes around break 
sites. These irradiation-induced foci serve as platforms to distribute 
the damage signal throughout the nucleus and activate appropriate 
repair mechanisms. In addition to organizing repair of DSBs, PIK3-
like kinases relay damage signals to p53, the major tumor suppres-
sor in mammalian cells (Lees-Miller et al., 1990). Under nonstressed 
conditions, p53 is kept at low levels by Mdm2-mediated protea-
somal degradation (Figure 1A; Haupt et al., 1997; Kubbutat et al., 
1997). When a cell encounters DNA damage, ATM, ATR, and DNA-
PK phosphorylate p53 and Mdm2. In addition, ATR and ATM acti-
vate the checkpoint kinases Chk1 and Chk2, respectively, which 
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pattern of kinase activation, each kinase may play a distinct role in 
controlling the dynamic response of p53. Alternatively, they may be 
able to compensate each other’s function in relaying the damage 
signal to preserve genomic integrity. Moreover, it is at present un-
clear to what extent these kinases function independently from each 
other or modulate each other’s activity in regard to p53 activation. 
Finally, we need to understand how the sensitizing effect of kinase 
inhibitors depends on the state of the targeted cell—for example, 
p53 mutations present in a given tumor.
To systematically address these questions, we used fluorescent 
reporters, live-cell time-lapse microscopy, and automated image 
analysis in combination with pharmacological perturbations to 
follow the p53 response upon induction of DSBs with ionizing 
γ-irradiation (IR) in individual cells with high temporal and spatial 
resolution. Using this approach, we found a new regulatory loop 
between DNA-PKcs, ATM, and p53 that contributes to sensitizing 
cells to radiation by increased induction of senescence.
RESULTS AND DISCUSSION
Inhibition of DNA-PKcs induces an amplified p53 response
To follow the p53 response over time, we used clonal cell lines sta-
bly expressing p53 fused to the yellow fluorescent protein Venus 
(p53-YFP; Supplemental Figure S1A). These included the trans-
formed cell lines A549, U-2 OS, and MCF7 (Batchelor et al., 2008; 
Chen et al., 2013), as well as the untransformed cell line MCF10A 
(this study). As previously reported, p53-YFP protein accumulated in 
regular pulses upon damage induction (Figure 1, B and C). To char-
acterize p53 dynamics, we analyzed hundreds of single-cell trajecto-
ries and extracted features such as pulse width and amplitude (Sup-
plemental Figure S1, B and C). Because p53 pulses are uniform over 
modify p53 as well (Kruse and Gu, 2009). Together these phosphor-
ylations prevent binding of p53 to Mdm2, which is instead degraded 
after autoubiquitination. p53 accumulates in the nucleus and acts as 
a transcription factor promoting the expression of genes involved in 
DNA repair, cell cycle arrest, apoptosis, and senescence in order to 
maintain genome integrity (Vousden and Prives, 2009). Among 
these p53 target genes is the negative regulator Mdm2, whose ex-
pression terminates the p53 response through a negative feedback 
loop. A second feedback loop exists between p53 and Wip1, a 
phosphatase that reverses phosphorylation by PI3K-like kinases (Lu 
et al., 2007; Batchelor et al., 2008). These two interlinked negative 
feedback loops shape the dynamic response of p53 to DSBs, result-
ing in pulsatile protein accumulations with uniform amplitudes and 
durations, independent of the degree of damage (Lahav et al., 
2004). When the properties of these p53 pulses were perturbed, 
either genetically or pharmacologically, the cellular response to 
damage was changed, highlighting the importance of p53 dynam-
ics for regulating cell fate decisions (Purvis et al., 2012; Borcherds 
et al., 2014).
Medically, induction of DNA damage is used as cancer treatment 
during chemotherapy and radiotherapy. A promising strategy to fur-
ther increase the efficiency of such treatments is to sensitize cancer 
cells by targeted perturbations of DDR pathways. Initial studies us-
ing in vitro models, xenografts, or first clinical trials demonstrated 
the feasibility of this approach for ATM, ATR, or DNA-PKcs inhibitors 
(Davidson et al., 2013; Weber and Ryan, 2015). However, to gain a 
deeper understanding of the molecular mechanisms underlying the 
sensitizing effect of these inhibitors, it is important to understand 
how the individual kinases interact with each other and with cell 
regulatory networks such as the p53 pathway. Owing to the complex 
FIGURE 1: ATM, ATR, and DNA-PK control the p53 response to DSBs. (A) Schematic overview of the p53 network in 
response to DSBs. (B) Time-lapse microscopy images of A549 cells expressing p53-YFP after treatment with 10-Gy γ-IR. 
(C) Individual A549 cells were tracked, and the p53 average nuclear fluorescence intensity was measured in cells 
untreated or treated with a mix of ATMi, ATRi, and DNA-PKi. (D) Quantification of the p53 average nuclear fluorescence 
intensity at 0, 3, and 5 h upon 10-Gy γ-IR in A549 cells untreated or treated with a mix of ATMi, ATRi, and DNA-PKi. Red 
lines indicate medians of distributions; boxes include data between the 25th and 75th percentiles; whiskers extend to 
maximum values within 1.5× the interquartile range; crosses represent outliers (>120 cells/condition).
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many DSBs (compare 2.5 to 10 Gy). In contrast, when DNA-PKcs 
was inhibited, the width and amplitude of p53 pulses increased in 
a dose-dependent manner (Figure 2C and Supplemental Figures 
S2, C and E–G, and S3, A–C).
To investigate further whether p53 dynamics is in general af-
fected by altered DSBs repair, we used an inhibitor against another 
component of the cNHEJ pathway, ligase IV (SCR7, LigIVi), which 
caused a decreased repair rate when applied to cells before geno-
toxic stress (Supplemental Figure S3D; Srivastava et al., 2012). How-
ever, cells treated with this inhibitor did not show changes in p53 
dynamics (Figure 2D and Supplemental Figure S3E), suggesting 
that an increase in unrepaired DSBs alone is not sufficient for ampli-
fying the p53 response.
As an alternative hypothesis, we considered that inhibiting DNA-
PKcs altered the interplay between the PI3K-like kinases. We there-
fore performed pairwise inhibition of all three kinases. When we in-
hibited both DNA-PKcs and ATR, we again observed longer and 
stronger accumulation of p53 compared with untreated cells (Figure 
3A and Supplemental Figure S3F). However, combining DNA-PKi 
and ATMi before damage induction surprisingly reverted the phe-
notype of DNA-PKcs inhibition: when we measured the resulting 
p53 response in living cells, we found that pulse duration was re-
duced from ∼200 min for cells treated with DNA-PKi alone to ∼100 
min as in controls (Figure 3B and Supplemental Figure S3G). The 
amplitude was similarly reduced. Inhibiting both ATM and ATR also 
resulted in p53 dynamics almost indistinguishable from that of 
untreated cells, albeit slightly more irregular (Figure 3C and Supple-
mental Figure S3H). These results indicate that ATR and DNA-PKcs 
alone induce regular p53 dynamics and are able to compensate the 
loss of the two other kinases. In contrast, p53 reacts more strongly 
to DNA damage when ATM is active in the absence of a functional 
DNA-PKcs kinase, independently of ATR’s state.
We hypothesized that this amplified p53 response is caused by 
hyperactivation of ATM in the presence of DNA-PKi. To test this, 
we measured ATM autophosphorylation at Ser-1981 and Chk2 
phosphorylation at Thr-68 as surrogates for ATM’s activation state 
and observed an increase in their levels after damage in the pres-
ence of DNA-PKcs inhibitor (Figure 3D), which was reverted by 
ATMi treatment. We then analyzed the levels of phosphorylated 
Chk2 and p53 over time in the presence and absence of DNA-PKi 
and observed a dramatic increase in the amount and duration of 
both modifications (Figure 3E). At the same time, protein levels of 
Mdm2, which is autodegraded in an ATM-dependent manner 
(Stommel and Wahl, 2004), were severely decreased. We verified 
that lower Mdm2 levels were due to posttranslational regulation 
by measuring its mRNA levels as well as mRNA levels of Wip1, 
another negative regulator of p53. As expected, we only observed 
minor differences during the first hours after damage (Supplemen-
tal Figure S4A). To understand whether ATM influences p53 dy-
namics through Mdm2, Chk2, or both, we analyzed the p53 re-
sponse in single cells upon simultaneous inhibition of Chk2 and 
DNA-PKcs. Because we still observed an amplified p53 response 
under this condition (Supplemental Figure S4, B and C), we con-
cluded that increased Chk2 activity is a secondary effect and not 
involved in altering p53 dynamics.
Taking the results together, we were able to show for the first 
time that inhibiting DNA-PKcs leads to a dose-dependent hyperac-
tivation of ATM upon DSBs induction, which induces Mdm2 degra-
dation and increased accumulation of p53. This new interplay be-
tween the two PI3K-like kinases could be mediated by direct 
modification of ATM or indirectly by a failure of DNA-PKcs to per-
form its function at the break site. It is well established that ATM can 
time, we report only the properties of the first response here. Our 
results confirmed that in A549 and MCF10A cells, features of the 
first p53 pulse are constant across increasing doses of γ-IR and 
therefore independent of the number of DSBs induced (Supple-
mental Figure S1, D and E; Lahav et al., 2004).
To systematically study the role of all three PI3K-like kinases in 
shaping the p53 response, we used well-characterized small-mole-
cule inhibitors (KU-55933, ATM inhibitor [ATMi]; VE-821, ATR inhibi-
tor [ATRi]; and NU 7026, DNA-PK inhibitor [DNA-PKi]) and con-
firmed their specificity using Western blot analysis (Supplemental 
Figure S1F; Hickson et al., 2004; Reaper et al., 2011). When we ap-
plied all three inhibitors together before treating cells with γ-IR, we 
no longer observed a p53 response in both A549 and MCF10A 
cells, as expected (Figure 1, C and D, and Supplemental Figure 
S1G). Next we investigated whether these kinases act as redundant 
systems to provide a fail-safe relay of the damage input to the p53 
system or whether each of them performs a distinct function. We 
first inhibited ATM, which has been described as the main kinase 
inducing p53 accumulation upon DSB induction (Ciccia and Elledge, 
2010). However, we did not observe qualitative differences in p53 
pulses (Figure 2A). When we quantified the first p53 pulse, we de-
tected only a slight reduction of pulse amplitude, whereas pulse 
duration remained unaltered (Figure 2B and Supplemental Figure 
S2, A, B, and D). This indicated that under the given experimental 
conditions, loss of ATM activity was compensated by the other PI3K-
like kinases, which is consistent with previous studies in ATM-defi-
cient cells (Li and Stern, 2005; Boehme et al., 2008; Callén et al., 
2009; Tomimatsu et al., 2009). Next we inhibited ATR. Again, we 
observed regular p53 pulses with only a small decrease in amplitude 
(Figure 2, A and B, and Supplemental Figure S2, A, B, and D). This 
compensation of ATR activity is in line with its secondary role during 
the DSB response, in which its function in the presence of ATM is 
restricted to contributing to damage repair by HR (Cimprich and 
Cortez, 2008).
When we finally inhibited DNA-PKcs, we unexpectedly ob-
served a strong alteration of p53 dynamics upon γ-IR: the first re-
sponse was longer and of increased amplitude across different 
transformed and untransformed cell lines (Figure 2, A and B, and 
Supplemental Figure S2, A–G). To validate these results, we used 
an alternative DNA-PKcs inhibitor (NU 7441, DNA-PKi-2) and ob-
served a similarly amplified response (Figure 2B and Supplemen-
tal Figure S2, A, B, and D). Moreover, we analyzed endogenous 
p53 by Western blot and confirmed higher p53 protein levels and 
a longer duration of the first response (Supplemental Figure S2H). 
Of interest, this increase in p53 levels was not noticed in previous 
studies (Zhu and Gooderham, 2006; Shaheen et al., 2011). Be-
cause these used measurements at constrained number of time 
points, the amplification of the p53 response might have been 
not as obvious as in the time-resolved, single-cell measurements 
presented here.
Loss of DNA-PK activity modulates the p53 response 
through prolonged activation of ATM
How does inhibition of a kinase involved in relaying the damage 
signal lead to an amplified p53 response? Because DNA-PKcs 
plays a critical role in cNHEJ and loss of its activity leads to a re-
duced repair rate (Loewer et al., 2013), we initially hypothesized 
that the observed changes in p53 dynamics might occur due to an 
increase in the number of DSBs. We therefore measured p53 dy-
namics in the presence or absence of DNA-PKi after damaging 
cells with different irradiation doses. In untreated cells, p53 accu-
mulation was hardly changed, even when we induced four times as 
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dent of DNA-PKcs function in NHEJ (Li et al., 2014). In any case, 
hyperactivation of ATM could serve as an important fail-safe mecha-
nism for insults that cannot be easily repaired, such as complex 
break sites consisting of multiple DSBs in close vicinity. In this case, 
hyperactivation of ATM might alter the repair pathway choice by 
forcing end resection (Zhou and Paull, 2013) and ensure that the 
presence of the severe damage is transmitted to response pathways 
such as p53.
phosphorylate DNA-PK at two defined S/TQ clusters and thereby 
regulate its activity within the cNHEJ pathway (Chen et al., 2007). It 
is conceivable that DNA-PKcs in turn phosphorylates ATM and in-
hibits it. Alternatively, it was previously shown that inactive DNA-
PKcs inhibits processing of DSBs, keeping them in an immature 
state (Jiang et al., 2015), which may continuously signal to and acti-
vate ATM. Of interest, a recent study reported ATM hyperactivation 
upon oxidative stress in DNA-PKcs–deficient cells, albeit indepen-
FIGURE 2: DNA-PKcs inhibition induces an amplified p53 response. (A) Individual A549 cells were tracked, and the 
average nuclear fluorescence was measured upon 10-Gy γ-IR in cells treated with ATMi, ATRi, or DNA-PKi as indicated. 
(B–D) Quantification of the relative amplitude and full-width at half-maximum (FWHM) of the first p53 pulse in A549 cells 
upon (B) 10-Gy γ-IR in cells untreated or treated individually with ATMi, ATRi, DNA-PKi, or DNA-PKi-2 (>130 cells/
condition), (C) 2.5, 5, or 10 Gy in cells untreated or treated with DNA-PKi (>730 cells/condition), or (D) 10-Gy γ-IR untreated 
or treated with LigIV inhibitor (>170 cells/condition). For statistical analysis, see Supplemental Figures S2 and S3.
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p53 accumulation upon DNA-PKcs inhibition modulates how cells 
react to DSBs, we first tested the induction of the p53 target 
genes p21, involved in cell cycle arrest, and YPEL3, involved in 
senescence. We observed strongly increased induction of both 
target genes in the absence of DNA-PKcs activity 1 and 2 d after 
Modulation of p53 dynamics leads to altered cell fate 
decision upon DSB induction
Previous studies showed that changes in p53 dynamics lead to 
altered expression of target genes and cell fate decisions (Purvis 
et al., 2012; Borcherds et al., 2014). To address whether altered 
FIGURE 3: Loss of DNA-PKcs activity modulates the p53 response through hyperactivation of ATM. (A–C) Individual 
trajectories and quantification of the relative amplitude and FWHM of the first p53 pulse upon 10-Gy γ-IR in A549 cells 
untreated or treated with (A) DNA-PKi and ATRi (>280 cells/condition), (B) DNA-PKi and ATMi (>260 cells/condition), or 
(C) ATMi and ATRi (>260 cells/condition) alone or in combination. (D) Analysis of ATM activity (measured by Western 
blotting with pATM- and pChk2-specific antibodies) in A549 cells untreated or treated with DNA-PKi and ATMi alone or 
a combination of both, followed by 10-Gy γ-IR. Asterisk indicates a nonspecific band. (E) Western blot analysis of Mdm2, 
pChk2, pp53, and GAPDH upon 10-Gy γ-IR in A549 cells untreated or treated with DNA-PKi. For statistical analysis, see 
Supplemental Figure S3.
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MATERIALS AND METHODS
Cells
We maintained all A549 and U-2 OS cell lines in McCoy’s 5A (GE 
Healthcare Life Sciences, Freiburg, Germany) plus 10% fetal calf 
serum (FCS; Thermo Fisher Scientific, Darmstadt, Germany); all 
MCF10A cell lines in DMEM/F-12 (Thermo Fisher Scientific) plus 5% 
horse serum (PAN-Biotech, Aidenbach, Germany), 20 ng/ml epidermal 
growth factor (EGF; Peptrotech, Hamburg, Germany), 0.5 μg/ml hydro-
cortisone (Sigma-Aldrich, München, Germany), 100 ng/ml cholera 
toxin (Sigma-Aldrich), and 10 μg/ml insulin (Sigma-Aldrich); and 
MCF7 cells in RPMI 1640 (Thermo Fisher Scientific) plus 10% FCS at 
37°C. All media contained penicillin and streptomycin. When appro-
priate, selective antibiotics (400 μg/ml G418 (Carl Roth, Karlsruhe, 
Germany), 50 μg/ml hygromycin (Thermo Fisher Scientific), or 
0.5 μg/ml puromycin [Carl Roth]) were added to maintain transgene 
expression.
The A549, U-2 OS (Chen et al., 2013), and MCF7 (Batchelor 
et al., 2008) p53-Venus reporter cell lines have been described be-
fore. We generated p53 fluorescent reporters in MCF10A by infect-
ing cells with lentiviruses encoding a construct in which p53 was 
fused to Venus fluorescent protein under the control of the human 
ubiquitin C promoter (UbCp).
We added nuclear markers to reporters by infecting with lenti-
viruses expressing histone 2B fused to cyan fluorescent protein 
(CFP) under the control of UbCp (A549, U-2 OS, and MCF10A) or 
a near-infrared fluorescent protein (iRFP) with a nuclear localization 
sequence under the control of the elongation factor 1-α promoter 
(MCF7). Subsequently, stable clonal cell lines were established and 
validated. A549 cells expressing p53 shRNA were produced by 
lentiviral infection and selection with puromycin (Brummelkamp 
et al., 2002).
irradiation (Figure 4A). Is this sufficient to change the fate of dam-
aged cells? We followed control and DNA-PKi–treated cells for 
3 d after irradiation with 5-Gy γ-IR and observed a dramatic de-
crease in proliferation in treated cells (Figure 4, B and C). In addi-
tion, they acquired a flattened morphology characteristic of se-
nescence and expressed senescence-associated β-galactosidase 
(Supplemental Figure S4D). The decrease in cell proliferation was 
mostly driven by p53, as the majority of cells lacking the tumor 
suppressor due to small interfering RNA–mediated knockdown 
were able to proliferate even in the presence of the inhibitor. 
Whereas combined treatment with DNA-PKcs and ATM inhibitors 
was sufficient to revert the amplified p53 response to acute dam-
age, it led to a p53-independent increase in senescence cells due 
to secondary effects during DNA repair.
It is well established that DNA-PKcs inhibition sensitizes cells 
for radiation (Davidson et al., 2013). However, this has been 
mainly attributed to its function in cNHEJ. Only few studies re-
ported that the radiosensitizing effect depends on the geno-
type—for example, the p53 status (Shaheen et al., 2011). Our 
results indicate that the observed radiosensitivity is at least in 
part caused by hyperactivation of ATM that causes an altered 
p53 response. This has implications for the use of DNA-PK inhibi-
tors in cancer therapies. Although tumors that retain a wild-type 
copy of p53 might respond well to a combination of radiotherapy 
and DNA-PKi, cells with mutated p53 might be less affected. On 
the contrary, neighboring healthy cells with intact p53 might be 
more severely affected in this scenario, increasing the side effects 
of tumor therapy. It will therefore be important to characterize 
the individual state of a given tumor to devise an efficient strat-
egy to specifically kill transformed cells while ensuring survival of 
neighboring tissues.
FIGURE 4: Prolonged p53 activation leads to altered cell fate decision upon DSB induction. (A) mRNA expression 
of p53 target genes p21 and YPEL3 was measured at days 1 and 2 in unirradiated A549 cells or upon 5-Gy γ-IR in 
cells untreated or treated with DNA-PKi. β-Actin was used as an internal control. Error bars indicate SD of technical 
triplicates. (B) Percentage of dividing A549 cells during 3 d after damage (5-Gy γ-IR) in wild-type (WT) or p53-knockdown 
(KD) conditions in the presence or absence of DNA-PKi. Error bars indicate SE of sample proportion. Initial number of 
cells, >125/condition. (C) Representative images of single A549 cells during 3 d upon 5-Gy γ-IR in cells untreated or 
treated with DNA-PKi in WT or p53 KD conditions. Blue boxes highlight the senescence-like phenotype observed in 
p53 WT cells treated with DNA-PKi.
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features of p53 dynamics such as amplitude or duration of protein 
accumulation pulses (Loewer et al., 2010). To determine the effect 
size and its significance for a given treatment, we calculated changes 
of the median pulse width and amplitude and performed permuta-
tion testing (1000 permutations) to establish corresponding 90% 
confidence intervals.
Reverse transcriptase quantitative PCR
We extracted mRNA using High Pure RNA Isolation kits (Roche, 
Mannheim, Germany). cDNA was generated using M-MuLV reverse 
transcriptase (NEB, Ipswich, MA) and oligo-dT primers. Quantitative 
PCR was performed in triplicate using SYBR Green reagent (Roche) 
on a StepOnePlus PCR machine (Thermo Fisher Scientific). Primer 
sequences were as follows: β-actin forward, GGC ACC CAG CAC 
AAT GAA GAT CAA; β-actin reverse, TAG AAG CAT TTG CGG TGG 
ACG ATG; Wip1 forward, ATA AGC CAG AAC TTC CCA AGG; Wip1 
reverse, TGG TCA ATA ACT GTG CTC CTT C; Mdm2 forward, AGA 
TGT TGG GCC CTT CGT GAG AA; Mdm2 reverse, GCC CTC TTC 
AGC TTG TGT TGA GTT; p21 forward, TGG ACC TGT CAC TGT 
CTT GT; p21 reverse, TCC TGT GGG CGG ATT AG; YPEL3 forward, 
GTG CCT ACC TCT TCA ACT CAG; and YPEL3 reverse, TGC TCT 
CAA AGG CCT GTT C.
Immunofluorescence
Cells were grown on coverslips coated with poly-l-lysine (Sigma-
Aldrich). The day of the experiment, they were fixed with 2% para-
formaldehyde (Carl Roth) and permeabilized with 0.1% Triton X-100 
(Carl Roth) in phosphate-buffered saline. We blocked with 10% goat 
serum (PAN-Biotech) and incubated with pH2A.X (Ser-319) over-
night at 4°C. Cells were washed, incubated with secondary antibody 
coupled to Alexa Fluor 647 (Thermo Fisher Scientific), and washed 
again. Finally, they were stained with Hoechst and embedded in 
Prolong Antifade (Thermo Fisher Scientific). Images were acquired 
with a 60× Plan Apo objective (NA 0.75) using appropriate filter sets. 
Automated segmentation was performed in Matlab (MathWorks) 
using algorithms from CellProfiler (Carpenter et al., 2006).
Cell proliferation assay
Cells were seeded 1.5 d before being treated with DMSO or DNA-
PKi and irradiated with 5-Gy γ-IR. Medium was changed every day, 
and the same randomly chosen cells were imaged at days 1, 2, and 3 
after irradiation by using gridded dishes and a Nikon Eclipse inverted 
microscope (Nikon) with a 4× objective. Initial numbers and fraction 
of dividing cells were manually quantified for each condition.
β-Galactosidase assay
Cells were seeded 2 d before being treated with DMSO or DNA-PKi 
and irradiated with 5 Gy γ-IR. Medium was changed every day. At 
day 3 after irradiation, cells were fixed with 2% paraformalde-
hyde/0.2% glutaraldehyde (Sigma-Aldrich) and incubated in stain-
ing solution (150 mM NaCl, 40 mM citric acid, 40 mM NaH2PO4, 
2 mM MgCl2, 5 mM K4(Fe(II)[CN]6), 5 mM K3(Fe(III)[CN]6), and 
1 mg/ml X-gal, all Carl Roth) for ∼20 h at 37°C. The fractions of 
stained cells were manually quantified for each condition using grid-
ded dishes.
For inhibitor treatments, we replaced the medium with a fresh 
one containing dimethyl sulfoxide (DMSO; Sigma-Aldrich; control), 
10 μM KU-55933 (ATMi; Axon Medchem, Groningen, Netherlands), 
2 μM VE-821 (ATRi; Selleckchem, München, Germany), 10 μM NU 
7026 (DNA-PKi; Biomol, Hamburg, Germany), 1 μM NU7441 (DNA-
PKi-2, DNA-PKcs inhibitor; Axon Medchem), 10 μM Chk2 inhibitor II 
(Chk2i II; Millipore, Darmstadt, Germany), and 100 μM SCR7 (LigIVi, 
ligase IV inhibitor; Xcess Biosciences, San Diege, CA) alone or in 
combination 30 min before irradiating cells using a cesium-137 γ-ray 
source.
Western blot analysis
We harvested cells, lysed them in the presence of protease and 
phosphatase inhibitors, and extracted proteins, which we quantified 
using bicinchoninic acid assay. Equal protein amounts were sepa-
rated by electrophoreses on 4–12% Bis-Tris or 3–8% Tris-acetate 
gradient gels (Thermo Fisher Scientific) and transferred to nitrocel-
lulose or polyvinylidene fluoride membranes (Carl Roth), respec-
tively, by electroblotting (overnight for Tris-acetate gels). We 
blocked membranes with 5% nonfat dried milk (Carl Roth) or 5% 
bovine serum albumin (Carl Roth) and incubated them overnight 
with primary antibody. The next day, we washed the membranes, 
incubated them with secondary antibody coupled to peroxidase, 
and washed them again. Protein levels were detected using chemi-
luminescence (ECL Prime, Amersham).
We used antibodies against total p53 (FL-393), Mdm2 (SMP14), 
and total DNA-PKcs (H163) from Santa Cruz Biotechnology (Dallas, 
TX); phospho-Chk1 (Ser-317), phospho-Chk2 (Thr-68), and phos-
pho-p53 (Ser-15) from Cell Signaling (Danvers, MA); phospho-ATM 
(S1981) from Rockland (Limerick, PA); phospho–histone H2A.X 
(Ser-319, JBW301) from Millipore; phospho-DNA-PKcs (S2056) 
from Abcam (Cambridge, MA); and glyceraldehyde-3-phosphate 
dehydrogenase from Sigma-Aldrich.
Time-lapse microscopy
We seeded cells in poly-d-lysine–coated glass-bottom plates 
(MatTek, Ashland, MA) 2 d before experiments. The day of the ex-
periment, medium was replaced with a fresh one without phenol red 
and riboflavin. We imaged cells on a Nikon Ti inverted fluorescence 
microscope (Nikon, Düsseldorf, Germany) with a Hamamatsu Orca 
R2 camera (Hamamatsu, Hamamatsu City, Japan) and a 20× Plan 
Apo objective (numerical aperture [NA] 0.75) using appropriate filter 
sets (Venus: 500/20-nm excitation [EX], 515-nm dichroic beam split-
ter [BS], 535/30-nm emission [EM]; CFP: 436/20-nm EM, 455-nm BS, 
480/40-nm EX; iRFP: 650/45-nm EM, 685-nm BS, 720/60-nm EX 
[Chroma]). The microscope was enclosed with an incubation cham-
ber to maintain constant temperature (37°C), CO2 concentration 
(5%), and humidity. Cells were imaged every 15 min for the duration 
of the experiment using Nikon Elements software.
Image and data analysis
Cells were tracked throughout the duration of the experiment using 
custom-written Matlab (MathWorks, Natick, MA) scripts based on 
code developed by the Alon lab (Cohen et al., 2008) and the Cell-
Profiler project (Carpenter et al., 2006). In brief, we applied flat-field 
correction and background subtraction to raw images before seg-
menting individual nuclei from nuclear marker images using adap-
tive thresholding and seeded watershed algorithms. Segmented 
cells were then assigned to corresponding cells in following images 
using a greedy match algorithm. Finally, we quantified the nuclear 
fluorescence intensity of p53-Venus for each cell over time and ana-
lyzed the resulting single-cell trajectories computationally to extract 
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Figure S1. (A) Scheme of the p53 fluorescent reporter construct. (B) Schematic drawing of 
the dynamic features (relative amplitude and full width at half maximum (FWHM)) of the 
first p53 pulse. (C) Image analysis example: cells are segmented according to the nuclear 
marker; segmented cells are assigned to corresponding cells at following time-points. See 
experimental procedures for details. (D-E) Quantification of the relative amplitude and 
FWHM of the first p53 pulse upon 2.5, 5 or 10 Gy ɣ-IR for (D) A549 (n > 250 cells per 
condition) or (E) MCF10A cells (n > 42 cells per condition). (F) Western blot analysis 
showing specificity of ATMi (measured by pATM and pChk2), of ATRi (measured by 
pChk1) and DNA-PKi (measured by pDNA-PK) in A549 cells. Cells were treated with 10 Gy 
ɣ-IR or 4.5 J/m2 ultraviolet (UV) radiation. (G) Quantification at 0, 3 and 5 hours of the p53 
average nuclear fluorescence intensity upon 10 Gy ɣ-IR in MCF10A cells untreated or treated 
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Figure S2. (A) Statistical analysis corresponding to Figure 2B. Estimated changes of the 
median pulse width and amplitude (red dots); error bars represent 90% confidence intervals. 
(B) Quantification of the relative amplitude and FWHM of the first p53 pulse upon 10 Gy ɣ-
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210 cells per condition). (C) Quantification of the relative amplitude and FWHM of the first 
p53 pulse upon 2.5, 5 or 10 Gy in cells untreated or treated with DNA-PKi in U-2 OS (n > 
250 cells per condition). (D-E) Statistical analysis corresponding to Figure S2B. and S2C. 
Estimated changes of the median pulse width and amplitude (red dots); error bars represent 
90% confidence intervals. (F-G) Quantification of the relative amplitude and FWHM of the 
first p53 pulse upon 5, 10 or 20 Gy in cells untreated or treated with DNA-PKi in MCF7 and 
corresponding statistical analysis (error bars represent 90% confidence intervals, n > 85 cells 
per condition). (H) Western blot analysis of total p53 upon 10 Gy ɣ-IR in A549 cells 
untreated or treated with DNA-PKi. 
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Figure S3. (A) Statistical analysis corresponding to Figure 2C. (B-C) Quantification of the 
relative amplitude and FWHM of the first p53 pulse upon 2.5, 5 or 10 Gy in cells untreated or 
treated with DNA-PKi in MCF10A cells and corresponding statistical analysis (error bars 
represent 90% confidence intervals, n > 28 cells per condition). (D) Quantification at 26 hours 
of the ɣH2A.X average nuclear fluorescence intensity upon 5 Gy ɣ-IR in A549 cells untreated 
or treated with LigIV inhibitor. (n > 340 cells per condition). (E-H) Statistical analysis 
corresponding to Figure 2D (E); 3A (F); 3B (G); 3C (H). Estimated changes of the median 
pulse width and amplitude (red dots); error bars represent 90% confidence intervals. 
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Figure S4. (A) mRNA expression of p53 negative feedback regulators Wip1 and Mdm2 was 
measured upon 10 Gy ɣ-IR in A549 cells untreated or treated with DNA-PKi. β-actin was 
used as an internal control. Error bars indicate standard deviation of technical triplicates. (B) 
Quantification of the relative amplitude and FWHM of the first p53 pulse upon 10 Gy ɣ-IR in 
A549 cells untreated or treated with DNA-PKi and Chk2i II alone or in combination. (n > 150 
cells per condition). (C) Statistical analysis corresponding to Figure S4B. Estimated changes 
of the median pulse width and amplitude (red dots); error bars represent 90% confidence 
intervals. (D) Percentage of β-galactosidase-positive A549 cells 3 days post damage (5 Gy ɣ-
IR) in wild-type (wt) or p53 knockdown (kd) conditions both in the presence or absence of 
DNA-PKi. Error bars indicate the standard deviation of three independent experiments with 
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